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EFFECTS OF STATIN THERAPY ON HOSPITALIZATION AND 
MORTALITY IN PATIENTS WITH DIABETES: A RETROSPECTIVE 
COHORT STUDY
Yang Y1, Banahan BF1, Pace PF2
1University of Mississippi, University, MS, USA, 2University of Mississippi, Oxford, MS, USA
OBJECTIVES: Clinical practice guidelines suggest that to achieve greater reductions 
in cardiovascular risk, statin therapy should be prescribed for diabetic patients at 
earlier stages. The objective of this study was to assess the inﬂuence of statin therapy 
on diabetes-speciﬁc hospitalization and all-cause mortality in diabetic patients enrolled 
in a state Medicaid program. METHODS: This is a retrospective cohort study of 
patients with diabetes using Medicaid pharmacy and medical claims data. Patients 
aged 40 years or older with a diagnosis of diabetes, who had continuous coverage in 
a state Medicaid program from January 2002 to December 2004, and who had a 
diagnosis of diabetes in 2002 were included in the study and were followed up until 
December 2004. Statin therapy was measured in using pharmacy claims data of 2003 
and statin use was deﬁned as at least two ﬁlled prescriptions for statin medications in 
2003. The primary outcomes of interest were diabetes-speciﬁc hospitalization and 
all-cause mortality in 2004. Multivariate regression analyses were performed to assess 
the impact of statin therapy on outcome measures. RESULTS: A total of 21,110 
patients met our inclusion criteria. Among them, 76.6% were females and the mean 
age was 62.9 (± 12.3) years. Less than 30% (28.7%) were prescribed statin medica-
tions in 2003. After controlling for baseline patient characteristics including age, 
gender, race, prior hospitalization, comorbidities (measured using Charlson comorbid-
ity index), and use of insulin, oral hypoglycemic agents, and antihypertensive medica-
tions, in comparison to non-users, statin users were 29.1% less likely to have 
diabetes-speciﬁc hospitalizations (OR: 0.719; 95%CI: 0.628–0.824). The odds for 
all-cause mortality were also lower in statin users as compared to non-users (OR: 
0.480; 95%CI: 0.327–0.705). CONCLUSIONS: The results of this study show that 
statin use rate is low among adults enrolled in a Medicaid program. Statin therapy 
in adult diabetic patients reduces diabetes-speciﬁc hospitalizations and all-cause 
mortality.
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AN OPEN-SOURCE, INTERACTIVE MODEL TO ASSESS THE OUTCOMES 
AND ECONOMICS OF DIABETES INTERVENTIONS IN CANADA
Hornberger J1, Shewade A1, Rickert JB1, Hammer M2, Groleau D3, Adams J3
1Cedar Associates LLC, Menlo Park, CA, USA, 2Novo Nordisk A/S, Bagsvaerd, Denmark, 
3Novo Nordisk Canada Inc., Mississauga, ON, Canada
OBJECTIVES: Several decision-theoretic models exist to assess the long-term out-
comes and economics of diabetic interventions. Since the models are proprietary, users 
are limited in their ability to critically review program code and modify inputs for 
their speciﬁc setting. The main objective was to develop a diabetes model with open-
source code that is unlocked, transparent, and modiﬁable by users, which are impor-
tant considerations for pharmaceutical decision makers, particularly in Canada. 
METHODS: The analytical framework is similar to the United Kingdom Prospective 
Diabetes Study (UKPDS)-based model (Clarke et al., Diabetologia 2004), and is 
created in Microsoft Excel, using visual basic. It is adaptable to both individual- and 
cohort-level data. Relationships between outcomes (e.g., myocardial infarction) and 
exogenous variables (e.g., HbA1c) were based on the equations as reported by Clark 
et al. The model was further modiﬁed to include (1) costs and disutilities associated 
with hypoglycemia and (2) options for emerging treatment intensiﬁcation regimens as 
the patient’s diabetes progresses. The model uses Canadian resource use data as 
defaults. The model was validated against the ﬁndings of the Ontario Diabetes Eco-
nomic Model (ODEM, http://www.path-hta.ca/diabetes.pdf, 2006). RESULTS: The 
quality-adjusted life-year gain of 8.23 for the control arm in published results of 
ODEM fell within the 95% conﬁdence interval of (8.20, 8.29) generated by the model. 
The corresponding results for life-years gained are also concordant. Unlike previous 
diabetes models, our model fulﬁlls Canadian drug submission requirements, speciﬁ-
cally the strict guidelines of the Common Drug Review (CDR) agency. CONCLU-
SIONS: An open-source, interactive diabetes model will greatly facilitate users’ 
– speciﬁcally clinicians and other decision makers – ability to modify inputs speciﬁc 
to their setting and rigorously assess the validity of ﬁndings.
PDB77
IDENTIFYING THE UNDERLYING FACTORS FOR DIABETES CARE AND 
ATTITUDES
Beaton SJ1, Sperl-Hillen JM2, Davis HT1, Von Worley A1, Fernandes OD2, Baumer D1, 
Spain V3
1LCF Research, Albuquerque, NM, USA, 2HealthPartners Research Foundation, Minneapolis, 
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OBJECTIVES: This paper used data from an ongoing Merck sponsored study evaluat-
ing the effectiveness of diabetes self management education (DSME): Journey for 
Control of Diabetes: the IDEA Study. During enrollment visits, patients with sub-
optimally controlled Type 2 diabetes (A1c < 7%) completed surveys with 19 attitudi-
nal and behavioral scales; clinical measures were also obtained. Although the primary 
outcome for DSME evaluation was A1c, we included the attitudinal/ behavioral survey 
to identify intervening variables. Our goal was to identify a set of underlying factors 
to efﬁciently explain attitudes and clinical outcomes. METHODS: A total of 623 
patients were enrolled from 2 sites, Minnesota and New Mexico. The baseline survey 
included the following instruments: general health (SF-12); depression (PHQ-9); Dia-
betes Empowerment (DES-SF); diabetes attitudes (DCP, 5 scales); personality (TIPI); 
Problem Areas in Diabetes (PAID); diet (RFS); physical activity (BRFSS); Readiness 
to Change; and hypoglycemia and hyperglycemia events (self-report). Several clinical 
measurements were also obtained (BMI, waist circumference, and A1c level). Data 
from the above sample were used to conduct a factor analysis. RESULTS: Factor 
analysis was performed using varimax orthogonal rotation using the survey and clini-
cal variables. Five factors were identiﬁed for the sample of 588 patients with measures 
on all variables. The ﬁrst factor related to “agreeable” personality characteristics from 
the TIPI; the second and fourth factors both related to poor physical health with the 
second factor including those items relating to empowerment and low A1c while the 
fourth factor included extroversion, low activity levels, and increased glycemic events. 
Factor three was high weight and waist circumference as well as low activity levels, 
and factor ﬁve was primarily readiness to change. Communality scores ranged from 
.317 to .829. CONCLUSIONS: Factor analysis can help explain underlying factors 
affecting patients with diabetes. Future analyses will use these factor scores to predict 
the effectiveness of DSME.
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RANDOMIZED CLINICAL TRIAL (RCT) DESIGN AND ANALYTIC ISSUES 
IMPACTING ASSUMED CLINICAL EFFECTS AND RESULTS OF 
COST-EFFECTIVENESS ANALYSES: ILLUSTRATION FROM A RECENT 
CANADIAN REPORT ON THE COST-EFFECTIVENESS OF BLOOD 
GLUCOSE TEST STRIPS FOR TYPE 2 DIABETES
Tunis S
IMS Health Inc., Falls Church, VA, USA
Most cost-effectiveness analyses of interventions in type 2 diabetes mellitus (T2DM) 
are based on clinical effects from randomized clinical trials (RCTs). While RCTs are 
conducted to minimize certain types of bias, protocol design and analytic approach 
can minimize the magnitude of treatment effect and thus, degree of projected long-term 
cost-effectiveness. The goal of this review was to provide a methodological critique 
of trials used in a recent report by The Canadian Optimal Medication Prescribing and 
Utilization Service (COMPUS) on the cost-effectiveness of blood glucose test strips for 
T2DM patients, and to discuss speciﬁc factors impacting input assumptions and model 
results. Seven RCTs were included in the COMPUS meta-analysis of non-insulin 
treated T2DM patients (n = 2,270). Assuming 1.29 strips/day and a weighted mean 
HbA1c effect of −0.25%, the base case incremental cost-utility ratio was $CAN 
113,643/QALY. Source trials varied widely in terms of patients’ ability to act upon 
monitoring results, and required and actual monitoring frequency. Several character-
istics of the trial most-heavily weighted in the COMPUS analysis illustrate how 
potential effects of monitoring may be obscured. The standardized protocol did not 
allow patients to obtain monitoring feedback and discuss it with health care providers 
in a timely fashion. Although assessed through intent-to-treat analyses, approximately 
half of HbA1c endpoint data attributed to the “intensive” monitoring group was 
provided by patients who had not been monitoring for an extended period. In contrast, 
strip costs used as model inputs were “maximized” by assuming 100% protocol 
adherence. Cost-effectiveness analyses of T2DM interventions can beneﬁt from a 
careful review of RCT design and analytic issues that may serve to underestimate 
clinical effects. Studies assessing the clinical value of monitoring should include pro-
tocols that optimize patients’ ability to act upon results, as well as analyses that link 
assumed clinical effects to actual monitoring frequency.
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OBJECTIVES: To determine the association of gastrointestinal (GI) bleed over one 
year in a cohort of Medicare/Medicaid dual eligibles (Duals) taking warfarin alone or 
warfarin & non-steroidal anti-inﬂammatory drugs (NSAIDS) and determine the 
annual health care costs for patients with GI bleed versus no GI Bleed. METHODS: 
Data were obtained from Arizona State Medicaid Agency from January 1, 2005 
through December 31, 2005. Inclusion criteria consisted of Duals ³65 and <90 years 
of age with at least two claims for warfarin. Duals were grouped as taking warfarin 
alone or warfarin plus NSAID. Factors examines included age, sex, race/ethnicity 
membership, rural or urban residence, with adjustment for total number of prescrip-
tion claims and comorbidities. Analysis was performed utilizing a logistic regression 
model to determine odds of GI bleed when taking warfarin compared to warfarin plus 
NSAID. RESULTS: A total of 2916 patients met inclusion/exclusion criteria: 2538 
taking warfarin alone and 378 taking warfarin plus NSAID. Males comprised 771 
(30.4%) of warfarin and 88 (23.3%) of warfarin plus NSAID groups. Mean age (SD) 
was 76.6 (6.8) and 74.0 (6.1) in the warfarin and warfarin plus NSAID groups 
respectively. There were 126 (5.0%) GI bleed events in the warfarin and 29 (7.7%) 
events in the warfarin plus NSAID groups (p = 0.02). The odds ratio for GI bleed was 
1.51 (0.98–2.33). Mean total annual health care costs (SD) were $13,232 (15,476) in 
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the warfarin and $10,195 (12,780) in the warfarin and NSAID groups (p < 0.01). 
CONCLUSIONS: This analysis did not identify a difference in the odds of having a 
GI bleed when on warfarin or warfarin plus NSAIDS. Unexpectedly, there were sig-
niﬁcantly lower costs for the warfarin plus NSAIDs group. These results should be 
interpreted with caution due to the small sample size and limitations of retrospective 
analysis.
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ADVERSE EVENTS OF PROMETHAZINE AND ONDANSETRON IN 
YOUNG CHILDREN AND WOMEN OF CHILD-BEARING AGE: A 
PHARMACOVIGILANCE STUDY BASED ON THE FDA ADVERSE EVENT 
REPORTING SYSTEM
Seddoh SA1, Guo JJ2, Ajayi FO3, Wigle P1
1University of Cincinnati, Cincinnati, OH, USA, 2University of Cincinnati Medical Center, 
Cincinnati, OH, USA, 3Procter & Gamble Company, Mason, OH, USA
OBJECTIVES: Pregnant women may use promethazine or ondansetron for nausea 
and vomiting during pregnancy (NVP). The long-term safety and its potential risks 
on the fetus and newborns are widely unknown. Promethazine has a black boxing 
warning for contraindicating its use in infants and young children. The purpose of 
this study was to quantify and describe adverse events (AEs) related to these two 
medications in child-bearing age women and young children. METHODS: The data 
source was the FDA’s Adverse Events Reporting System database from 1997 to 2006. 
Using a retrospective data analysis, AEs for all patients with study drugs were com-
pared to that for children ages 0–6 years old and women of child-bearing age (CBA) 
15- 50 years old. The annual frequencies of AEs for both study drugs were analyzed 
and stratiﬁed by age group and gender. The related AEs were categorized by clinical 
outcomes, pregnancy outcomes, route of administration, and duration of therapy. 
RESULTS: A total of 392,229 AEs for promethazine and 282,056 AEs for ondanset-
ron were reported. Of those, 13.7% of ondansetron and 22% promethazine AEs were 
for CBA women with the peak for age 35–50; while 13.1% ondansetron and 13.8% 
promethazine AEs were for children age 0–6 with the peak for age 0–2. There were 
23.68% and 13.54% AEs related to promethazine and ondansetron long-term use 
(greater than 90 days) among CBA women, respectively. The most common routes of 
administration were oral and intravenous. For CBA women, the frequent AE preg-
nancy outcomes were maternal complications (26%), premature labor (9%), maternal 
drugs affecting fetus (8%) and spontaneous abortion (4%); while the most frequent 
AEs for children were neonatal respiratory arrest (0.25%) and neonatal apneic attack 
(0.17%). CONCLUSIONS: AEs of promethazine and ondansetron among children 
and CBA women are common. The risk of their off-label use for the long-term treat-
ment of NVP should be recommended with cautions.
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PREVALENCE, COSTS AND SERVICES OF COMORBID CONDITIONS 
ASSOCIATED WITH FUNCTIONAL DYSPEPSIA
Brook RA1, Talley NJ2, Choung RS3, Smeeding J4, Melkonian AK5, Kleinman NL6
1The JeSTARx Group, Newfoundland, NJ, USA, 2Mayo Clinic Jacksonville, FL, Rochester, MN, 
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OBJECTIVES: The etiology of functional dyspepsia (FD) is debated. However, no 
published data exist on the associated co-morbid conditions with FD. This study aimed 
to assess the prevalence, services, and costs related to co-morbid conditions associated 
with FD. METHODS: Retrospective database analysis on a 4-year study period, from 
January 1, 2001, through December 31, 2004 using payroll data and adjudicated 
health insurance medical and prescription claims on more than 300,000 employees. 
Study comparisons were performed among employees with FD and propensity-score-
matched employees without FD (controls). Outcome measures included the preva-
lence, costs and utilization of health services for various comorbid conditions as 
deﬁned by the Agency for Healthcare Research and Quality (AHRQ). RESULTS: 
Employees in cohort FD (N = 1669) and a 50:1 matched control-cohort (N = 83,450) 
were compared. Employee with FD were more likely to have all major diagnostic 
categories (MDC) including digestive system, blood and blood forming organs, mental 
disorders, infections and parasitic disease, etc. except pregnancy and prenatal related 
disease, compared to matched controls. The top MDC prevalence ratios between the 
two groups were for digestive systems (6.3:1), blood and blood form organs (2.6:1), 
mental disorders (2.1:1), and infectious & parasitic disease (2.0:1). More interestingly, 
18 of the top 30 most prevalent AHRQ “speciﬁc” categories were non-speciﬁc with 
the terms like “other” or “undeﬁned” in the title. Moreover, annual medical costs for 
the FD cohort were greater than for controls in 155 (59%) of the 261 AHRQ’s Speciﬁc 
Categories and signiﬁcantly greater (P ≤ 0.05) in 76 categories (29%). Similarly, the 
services were greater for 179 (69%) of the 261 Speciﬁc Categories and signiﬁcantly 
greater (P ≤ 0.05) in 110 categories (42%). CONCLUSIONS: Thisstudy showed excess 
comorbidity in employees with FD compared to employees without FD, might be a 
major determinant factors for excess health-care services and health-care costs of 
functional dyspepsia.
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SYSTEMATIC REVIEW AND META-ANALYSIS OF PUBLISHED 
RANDOMIZED CONTROLLED TRIALS COMPARING THE EFFICACY OF 
PEGINTERFERON-ALPHA-2A VERSUS PEGINTERFERON ALPHA-2B 
BOTH PLUS RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS
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OBJECTIVES: Hepatitis C affects approximately 180 million people worldwide. It is 
one of the main causes of liver disease and is the predominant etiology for liver 
transplantation. This study performs a systematic review and meta-analysis of pub-
lished randomized controlled trials comparing efﬁcacy of peginterferon-alpha-2a 
versus peginterferon-alpha-2b both in association with ribavirin in order to assess 
which is more effective in the treatment of HCV infection. METHODS: A thorough 
search in MEDLINE, Lilacs, Cochrane library and Embase databases was conducted 
in the last quarter of 2009. Manual searches in specialized websites were also carried 
out. Included studies were those which evaluate treatment efﬁcacy of peginterferon 
alpha-2a versus peginterferon alpha-2b both plus ribavirin for hepatitis C treatment 
in naïve patients or nonresponders to other therapies not co-infected with HIV. 
According to heterogeneity test, a ﬁxed or a random-effect models was adopted for 
meta-analysis. RESULTS: A total of 570 citations (databases citation without dupli-
cates plus manual searches) were found but only seven met the inclusion criteria: 1) 
Ascione, 2009; 2) Rumi, 2009; 3) McHutchison, 2009; 4) Yenice, 2006; 5) Scotto, 
2008; 6) Kolakowska, 2008; 7) Berak, 2007. All studies are randomized controlled 
trials. Overall, peginterferon-alpha-2a has shown higher sustained virological response 
(SVR) as compared to peginterferon-alpha-2b: 51.7% versus 42.4% (RR = 1.23, IC 
95% 1.10 – 1.38, assuming a ﬁxed-effect model). For genotypes 1/4: 42.1% versus 
33.3% (RR = 1.11, IC 95% 1.02 – 1.20, assuming a ﬁxed-effect model) and for geno-
types 2/3: 79.2% versus 73.8% (RR = 1.11, IC 95% 1.01 – 1.22, assuming a ﬁxed-
effect model). CONCLUSIONS: These ﬁndings suggest that peginterferon-alpha-2a is 
associated with a higher clinical response than peginterferon-alpha-2b indicating that 
it should be used as the standard-of-care therapy. Our results are in line with another 
recent published systematic review (Awad, 2009) which concluded that peginterferon-
alpha-2a has a higher SVR as compared to peginterferon-alpha-2b, with similar safety 
proﬁle.
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A META-ANALYSIS OF THE 5-HT3 RECEPTOR ANTAGONISTS USE IN 
POST-OPERATIVE NAUSEA AND VOMITING PROPHYLAXIS
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OBJECTIVES: To investigate whether the 5-HT3 receptor antagonists—ondansetron, 
granisetron, tropisetron, and dolasetron—used for the prevention of post-operative 
nausea and vomiting (PONV) differ in efﬁcacy. METHODS: A meta-analysis was 
conducted using published studies. A systematic literature search within Pubmed and 
the Cochrane Library for randomized, controlled, double-blinded studies measuring 
efﬁcacy in terms of PONV prophylaxis was conducted. The odds of patients exempted 
from PONV and post-operative vomiting (POV) within each study arm 24 hours after 
surgery were the primary indices of drug efﬁcacy. Indirect comparisons using random 
effect models were conducted. Subgroup analyses excluding controversial studies and 
controlling amount of dose and administration route were also conducted. RESULTS: 
A total of 82 studies were identiﬁed, representing 15,709 patients. In terms of prevent-
ing PONV, the analysis indicated that granisetron was statistically signiﬁcantly better 
than ondansetron (odds ratio(OR) = 1.46, 95% conﬁdence interval(CI):1.08–2.00) 
and dolasetron(OR = 1.56, 95%CI: 1.03–2.34); no other statistically signiﬁcant rela-
tionships comparing either two of the four drugs were found. In terms of preventing 
POV, the four antiemetic drugs had comparable efﬁcacy: granisetron showed similar 
efﬁcacy as compared to ondansetron(OR = 1.61, 95%CI: 0.99–2.63), tropisetron(OR 
= 1.70, 95%CI: 0.95–3.05) and dolasetron(OR = 1.35, 95%CI: 0.78–2.27); ondanset-
ron exhibited comparable efﬁcacy as compared to tropisetron(OR = 1.06, 95%CI: 
0.63–1.79) and dolasetron(OR = 0.84, 95%CI = 0.52–1.31); tropisetron and dolas-
etron were also similar in efﬁcacy(OR = 0.80, 95%CI = 0.44–1.37). Subgroup analyses 
also found that the four drugs did not differ in efﬁcacy. All 5-HT3 receptor antagonists 
were statistically signiﬁcantly better than placebo. CONCLUSIONS: With respect to 
PONV prophylaxis, granisetron was statistically signiﬁcantly better than ondansetron 
and dolasetron; ondansetron, tropisetron, and dolasetron exhibit similar efﬁcacy. With 
respect to POV prophylaxis, ondansetron, granisetron, tropisetron, and dolasetron 
appeared to have comparable efﬁcacy.
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TEMPORAL CHANGES IN SURGICAL PROCEDURES FOR MANAGEMENT 
OF DIVERTICULAR DISEASE
Chung JK, Knight TK, Nichol MB
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: Research has suggested that admissions for diverticular disease (DD) 
are on the rise in Western countries, particularly among a younger patient population. 
However, relatively little is known about how this increase has impacted the use of 
surgical procedures for the management of DD. The goals of this study were a) to 
determine temporal trends in the use of surgical procedures (laparoscopic colectomy 
[LC] and open colectomy [OC]) for DD, and b) to investigate temporal changes in 
